Issue 142 • May 2024

Anticipation rises for RSV rollout as positive data emerges

Following major successes in the RSV landscape over the last few years, regulators debate rollout plans

Briefing

Genmab joins ADC arena with $1.8bn ProfoundBio acquisition

Feature

Molecular glues are the latest craze in pharma research, but what are they?

Comment

Lenmeldy becomes world’s most expensive drug

Interview

BARDA wants to back tech that can combat multiple infections, says director

Go to article: Home | Anticipation rises for RSV rollout as positive data emergesGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Avenga Company InsightGo to article: In DepthGo to article: Anticipation rises for RSV rollout as positive data emergesGo to article: Continuous monitoring expands aseptic knowledge and data in real time Go to article: Molecular glues are the latest craze in pharma research, but what are they?Go to article: Using pharmacovigilance to turn reactive investigation into active discoveryGo to article: Lenmeldy becomes world’s most expensive drug Go to article: Q&A: BARDA wants to back tech that can combat multiple infections, says director Go to article: Sponsored SupplementsGo to article: ZETAGo to article: NiproGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue